SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck
MRK 98.96-0.8%Dec 8 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (1082)12/9/1998 4:28:00 PM
From: Rob L.  Read Replies (1) of 1580
 
Those numbers suggest Merck is grossly overvalued. At $4.95 the PE is around 32 and the earnings growth is only 14%. Either price has to come down or earnings have to go up. CEO says earnings estimates are reasonable which means MRK will probabably beat them, but not by enough to bring the stock down to earth. The only chance this stock has is if the blockbuster drugs develop into something unexpected. Those that put a buy out on this company at these prices are misleading investors IMO. I might consider taking some profits after digesting all of this news.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News